Merck KGaA, Darmstadt, Germany has agreed to acquire Silence Therapeutics in an all-cash deal that values the biotech’s equity at about $1.3 billion, a price that says as much about pharmaceutical strategy as it does about any one clinical result. Under the terms disclosed in Silence’s SEC-filed announcement, Merck will pay $20 per American Depositary Share, with each ADS representing three Silence ordinary shares. That is a 130% premium to Silence’s October 16 closing price and an 82% premium to its 30-day volume-weighted average price of $10.99.
Why it matters is straightforward: Merck is not buying approved sales. It is buying the chance to turn a promising RNA-silencing drug candidate for a rare blood cancer into a phase-3-proven medicine, while also acquiring a broader siRNA platform and development team. The real question for investors, clinicians, and competitors is whether this is mainly a near-term drug acquisition, a longer-term platform deal, or an expensive option on both.
The transaction is structured as a U.K. scheme of arrangement and is expected to close in the first quarter of 2027, subject to shareholder, court, regulatory, and other customary approvals. Silence’s board unanimously approved it, and holders of about 14% of the company’s voting power have signed a voting and support agreement. That backing helps, but it does not make closing automatic.
Why Merck is paying up now
The core of the deal is divesiran, Silence’s lead program for polycythemia vera, a rare blood cancer in which the bone marrow produces too many red blood cells. Silence uses what it calls its mRNAi GOLD platform to design small-interfering RNA medicines aimed at silencing disease-related genes, especially in the liver. In practical terms, an siRNA molecule guides a cellular complex to a target messenger RNA; lowering that message can lower production of the corresponding protein.
Divesiran targets TMPRSS6 in liver cells. The intended effect is to redirect iron away from the bone marrow and reduce excessive red-blood-cell production in polycythemia vera. That mechanism matters because patients with the disease may need regular therapeutic blood draws to keep blood counts under control. If a drug can reduce that burden and do so with relatively infrequent dosing, the clinical and commercial appeal rises.
That convenience story is part of what Merck appears to be buying. Silence reported mid-stage results in August, and Fierce Biotech said 88% of patients in the phase-2 study met the response criteria between weeks 18 and 36. The reported response rate was 93.8% in an every-six-weeks cohort and 81.3% in an every-12-weeks cohort. Those figures are encouraging enough to support a premium takeout, especially when paired with the possibility that divesiran could be dosed less often than a rival weekly injection.
But the deal terms also show that Merck is paying for more than one readout. The company said the acquisition will strengthen its specialty and rare-disease pipeline and extend its external-innovation strategy. Reuters, in reporting carried by Euronext, described this as Merck’s third major acquisition in less than two years, after the 2025 purchase of SpringWorks Therapeutics and the pending takeover of Bio-Techne. In other words, this fits a broader pattern: Merck is using deals to add assets that could matter in specialist markets where clinical differentiation, regulatory execution, and commercial focus can still create meaningful value.
What divesiran still has to prove
The premium should not be mistaken for clinical closure. The public announcement does not include the full phase-2 dataset, and that missing detail is exactly where a billion-dollar thesis becomes a testable one.
What is not yet public includes the study size, the comparator or randomization design, the duration of follow-up, adverse events, discontinuations, phlebotomy or transfusion requirements, and the statistical confidence around the reported response rates. Without that, the phase-2 numbers do not establish superiority to Takeda and Protagonist’s Mimrylo, which Fierce reported received FDA approval in August 2026. Nor do they answer whether the benefit is durable enough, safe enough, or practical enough to support a broad launch.
The next step is not just “run phase 3.” Merck now has to decide what phase 3 is supposed to prove and how. It is not yet known whether divesiran will keep the every-six-weeks or every-12-weeks interval in late-stage testing, which endpoints regulators will require, or how the study will treat patients who respond incompletely. Those choices will shape both the approval path and the eventual label.
Then comes the less glamorous part of drugmaking that often determines whether a good mechanism becomes a real business. Merck must show it can manufacture the therapy at scale, deliver it reliably, and support reimbursement in a market where an approved competitor already exists. Even if less frequent dosing holds up, the commercial payoff is not automatic. Payers may judge products differently on efficacy, safety, monitoring burden, or price. Clinicians may be cautious about switching stable patients. Patients may value convenience differently than business-development models assume.
The platform is part of the price
Treating this as a one-drug acquisition misses part of the logic. Silence’s disclosed pipeline also includes zerlasiran, aimed at people with high lipoprotein(a), and SLN312 for dyslipidemia. Merck is effectively buying a lead program plus a liver-targeted siRNA toolkit that could generate or support future programs.
That broader platform helps explain why Merck paid a 130% premium to the last close. The price is not a direct forecast of divesiran sales or a verdict that approval is likely. It reflects strategic optionality: Merck is acquiring the right to deploy its capital, regulatory infrastructure, manufacturing capacity, and commercial reach against a platform that might yield more than one specialty medicine.
Still, platform value should not be romanticized. Fierce noted that future development of zerlasiran was in limbo after a collaboration ended, and that AstraZeneca returned rights to SLN312. Those details do not erase the technology’s appeal, but they do show the usual biotech pattern: a platform can be strategically attractive even when not every program advances smoothly.
That is why the most useful way to read the deal is as a bet with multiple checkpoints. If Merck can carry divesiran through phase 3, preserve whatever dosing advantage proves real, manufacture it at the intended scale, and win adoption against an approved rival, the acquisition will look like a well-timed purchase of both a near-term medicine and a platform engine. If late-stage data, manufacturing, reimbursement, or uptake disappoint, the same premium will look like the price of buying promise before proof.
By
By
By
By
By
